Trials / Completed
CompletedNCT03217591
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Akebia Therapeutics · Industry
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-1973 | Oral Tablet |
| DRUG | IW-1973 | Oral Tablet |
| DRUG | Placebo | Oral Tablet |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2019-08-20
- Completion
- 2019-08-20
- First posted
- 2017-07-14
- Last updated
- 2022-09-15
- Results posted
- 2022-09-15
Locations
54 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03217591. Inclusion in this directory is not an endorsement.